Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2017 Summary According to the recently published report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017'; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex. The report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017' outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Lymphoma, Colon Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liposarcoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Anaplastic Oligoastrocytoma, Bacterial Infections, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Leukemias, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myelosuppression, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Oropharyngeal Cancer, Peritoneal Cancer, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer. Scope - The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics and enlists all their major and minor projects - The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development Beta Pharma Inc Eli Lilly and Company FLX Bio Inc G1 Therapeutics Inc Jiangsu Hengrui Medicine Co Ltd Novartis AG Onconova Therapeutics Inc Pfizer Inc Teijin Pharma Ltd Tiziana Life Sciences Plc ViroStatics srl XuanZhu Pharma Co Ltd Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles abemaciclib - Drug Profile Product Description Mechanism Of Action R&D Progress BPI-1178 - Drug Profile Product Description Mechanism Of Action R&D Progress C-1748 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-925 - Drug Profile Product Description Mechanism Of Action R&D Progress G-1T100182 - Drug Profile Product Description Mechanism Of Action R&D Progress G-1T100183 - Drug Profile Product Description Mechanism Of Action R&D Progress G-1T101551 - Drug Profile Product Description Mechanism Of Action R&D Progress G-1T38 - Drug Profile Product Description Mechanism Of Action R&D Progress GZ-381 - Drug Profile Product Description Mechanism Of Action R&D Progress HEC-80797 - Drug Profile Product Description Mechanism Of Action R&D Progress milciclib - Drug Profile Product Description Mechanism Of Action R&D Progress ON-123300 - Drug Profile Product Description Mechanism Of Action R&D Progress palbociclib - Drug Profile Product Description Mechanism Of Action R&D Progress ribociclib succinate - Drug Profile Product Description Mechanism Of Action R&D Progress SHR-6390 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress SRX-3177 - Drug Profile Product Description Mechanism Of Action R&D Progress trilaciclib - Drug Profile Product Description Mechanism Of Action R&D Progress voruciclib - Drug Profile Product Description Mechanism Of Action R&D Progress VS-2370 - Drug Profile Product Description Mechanism Of Action R&D Progress Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones Featured News & Press Releases May 17, 2017: Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib at ASCO 2017 May 04, 2017: Breast Cancer Drug Palbociclib could be Temporarily Available to NHS Patients for Free Apr 25, 2017: SignalRx to Present at the 12th Annual Drug Discovery Chemistry 2017 Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma Apr 24, 2017: Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Demonstrated Superior Progression-Free Survival At Interim Analysis Apr 21, 2017: Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumors Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting Apr 03, 2017: SignalRx to Present at the AACR Annual Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer Mar 31, 2017: IBRANCE (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer Mar 20, 2017: Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival Mar 17, 2017: KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, Available for Order At Biologics Mar 13, 2017: Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval Mar 13, 2017: Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor Feb 03, 2017: Breast cancer drug costs too high in relation to benefits for routine NHS funding Jan 10, 2017: G1 Therapeutics Initiates Phase 2 trial of Trilaciclib in Triple-Negative Breast Cancer Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Beta Pharma Inc, H1 2017 Pipeline by Eli Lilly and Company, H1 2017 Pipeline by FLX Bio Inc, H1 2017 Pipeline by G1 Therapeutics Inc, H1 2017 Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Pipeline by Novartis AG, H1 2017 Pipeline by Onconova Therapeutics Inc, H1 2017 Pipeline by Pfizer Inc, H1 2017 Pipeline by Teijin Pharma Ltd, H1 2017 Pipeline by Tiziana Life Sciences Plc, H1 2017 Pipeline by ViroStatics srl, H1 2017 Pipeline by XuanZhu Pharma Co Ltd, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
